Current Protein Identity：Q16552
New Search
Difference tags compare only the current result set; every original PDB and assembly record remains separate.
Related-Structure Differences
Each row represents one biological assembly in one PDB entry; multiple monomers of the same protein are listed separately.
| PDB Entry | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Experimental Method | Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 2VXS Structure of IL-17A in complex with a potent, fully human neutralising antibody Deposited 2008-07-09 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain C
20–155（136 aa）
Fragment：RESIDUES 20-155
Chain D
20–155（136 aa）
Fragment：RESIDUES 20-155
|
Not recorded | SO4 SULFATE ION × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
90.9 MM PCTP BUFFER PH 4.0, 9.1 MM PCTP BUFFER PH 9.5, 100 MM AMMONIUM SULPHATE, 14% W/V PEG3350
|
Resolution 2.63 Å R-free 0.264 |
| 2VXS Structure of IL-17A in complex with a potent, fully human neutralising antibody Deposited 2008-07-09 | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain A
20–155（136 aa）
Fragment：RESIDUES 20-155
Chain B
20–155（136 aa）
Fragment：RESIDUES 20-155
|
Not recorded | SO4 SULFATE ION × 8 | X-RAY DIFFRACTION |
X-ray crystallization conditions
90.9 MM PCTP BUFFER PH 4.0, 9.1 MM PCTP BUFFER PH 9.5, 100 MM AMMONIUM SULPHATE, 14% W/V PEG3350
|
Resolution 2.63 Å R-free 0.264 |
| 4HR9 Human interleukin 17A Deposited 2012-10-26 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Mutation：N45D, C106S Mutation：N45D, C106S | No recorded non-water small molecule | X-RAY DIFFRACTION | mmCIF provides none of the parsed conditions | Resolution 2.48 Å R-free 0.233 |
| 4HSA Structure of interleukin 17a in complex with il17ra receptor Deposited 2012-10-29 | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Mutation：N45D, C106S Mutation：N45D, C106S | No recorded non-water small molecule | X-RAY DIFFRACTION | mmCIF provides none of the parsed conditions | Resolution 3.15 Å R-free 0.232 |
| 4HSA Structure of interleukin 17a in complex with il17ra receptor Deposited 2012-10-29 | Assembly 2 Other combination Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain D
34–155（122 aa）
Chain E
34–155（122 aa）
|
Mutation：N45D, C106S Mutation：N45D, C106S | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 | X-RAY DIFFRACTION | mmCIF provides none of the parsed conditions | Resolution 3.15 Å R-free 0.232 |
| 4QHU Crystal Structure of IL-17A/Fab6785 complex Deposited 2014-05-29 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain C
24–154（131 aa）
Chain D
24–154（131 aa）
|
Mutation：K70Q Mutation：K70Q | GOL GLYCEROL × 5 CL CHLORIDE ION × 1 SO4 SULFATE ION × 5 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；298 K；0.1 M sodium acetate, 12% PEG 5000, 0.2 M lithium sulfate, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.216 |
| 5HHV Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide Deposited 2016-01-11 | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count |
Chain A
34–155（122 aa）
Fragment：UNP residues 34-155
Chain B
34–155（122 aa）
Fragment：UNP residues 34-155
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；.02 mM CdCl2, 0.02 M MgCl2, 0.02 M NiCl2, 0.1 M NaOAc pH=4.2-4.9, and 24-28 % PEG MME 2000
|
Resolution 2.20 Å R-free 0.236 |
| 5HHX Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide Deposited 2016-01-11 | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count |
Chain A
18–155（138 aa）
Fragment：UNP residues 20-155
Chain B
18–155（138 aa）
Fragment：UNP residues 20-155
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；0.1 M NaOAc, pH=4.5 and 30% PEG MME 5000
|
Resolution 3.00 Å R-free 0.263 |
| 5HI3 Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Deposited 2016-01-11 | Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric（7） Consistent with protein count |
Chain A
24–155（132 aa）
Fragment：UNP residues 24-155
Chain B
24–155（132 aa）
Fragment：UNP residues 24-155
|
Not recorded | 63O N-(4-{2-[({1-[2-(dimethylamino)-2-oxoethyl]cyclopentyl}acetyl)amino]ethyl}phenyl)-2-fluoro-Nalpha-[(1-methyl-1H-pyrazol-5-yl)carbonyl]-L-phenylalaninamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；10% 2-propanol, 20-24% PEG 6K, 0.1 M sodium acetate pH=4.0-5.0
|
Resolution 2.15 Å R-free 0.231 |
| 5HI4 Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Deposited 2016-01-11 | Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric（7） Consistent with protein count |
Chain A
24–155（132 aa）
Fragment：UNP residues 24-155
Chain B
24–155（132 aa）
Fragment：UNP residues 24-155
|
Not recorded | 63P (9'S,17'R)-6'-chloro-N-methyl-9'-{[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino}-10',19'-dioxo-2'-oxa-11',18'-diazaspiro[cyclopentane-1,21'-tetracyclo[20.2.2.2~12,15~.1~3,7~]nonacosane]-1'(24'),3'(29'),4',6',12',14',22',25',27'-nonaene-17'-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；10% 2-propanol, 20-24% PEG 6K, 0.1 M sodium acetate pH=4.0-5.0
|
Resolution 1.80 Å R-free 0.224 |
| 5HI5 Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists Deposited 2016-01-11 | Assembly 1 Protein heterocomplex Heteromer；Protein × 7 PDB declaration: heptameric（7） Consistent with protein count |
Chain A
24–155（132 aa）
Fragment：UNP residues 24-155
Chain B
24–155（132 aa）
Fragment：UNP residues 24-155
|
Not recorded | 63Q (4S,20R)-7-chloro-N-methyl-4-{[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino}-3,18-dioxo-2,19-diazatetracyclo[20.2.2.1~6,10~.1~11,15~]octacosa-1(24),6(28),7,9,11(27),12,14,22,25-nonaene-20-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.5；293 K；10% 2-propanol, 20-24% PEG 6K, 0.1 M sodium acetate pH=4.0-5.0
|
Resolution 1.80 Å R-free 0.219 |
| 5N7W Computationally designed functional antibody Deposited 2017-02-21 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain X
1–155（155 aa）
Chain Y
1–155（155 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.5；293 K；18% (w/v) PEG-MME 2000, 100mM PCTP pH4.5
|
Resolution 1.96 Å R-free 0.250 |
| 5N92 Crystal Structure of Human IL-17AF Deposited 2017-02-24 | Assembly 1 Other combination Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
24–155（132 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；293 K；0.1M Bis-Tris-Propane, 0.5M Succinic acid, pH 7.0
|
Resolution 2.30 Å R-free 0.241 |
| 5NAN Crystal Structure of human IL-17AF in complex with human IL-17RA Deposited 2017-02-28 | Assembly 1 Other combination Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain A
24–155（132 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate
|
Resolution 3.30 Å R-free 0.243 |
| 5NAN Crystal Structure of human IL-17AF in complex with human IL-17RA Deposited 2017-02-28 | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric（3） Consistent with protein count |
Chain D
24–155（132 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7.5；293 K；0.1M HEPES, 15% PEG MME 5,000, 0.05M Ammonium Acetate
|
Resolution 3.30 Å R-free 0.243 |
| 5VB9 IL-17A in complex with peptide Deposited 2017-03-28 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain A
38–155（118 aa）
Fragment：UNP residues 38-155
|
Not recorded | EDO 1,2-ETHANEDIOL × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；281 K；Protein at 7.1 mg/ml in 10mM Bis-Tris pH 6.5, 10% glycerol, 150mM NaCl with 2 mM of peptide, equilibrated against a reservoir containing 20% PEG 3350 and 200mM Lithium Chloride.
|
Resolution 1.70 Å R-free 0.211 |
| 5VB9 IL-17A in complex with peptide Deposited 2017-03-28 | Assembly 2 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain B
38–155（118 aa）
Fragment：UNP residues 38-155
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 CL CHLORIDE ION × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；281 K；Protein at 7.1 mg/ml in 10mM Bis-Tris pH 6.5, 10% glycerol, 150mM NaCl with 2 mM of peptide, equilibrated against a reservoir containing 20% PEG 3350 and 200mM Lithium Chloride.
|
Resolution 1.70 Å R-free 0.211 |
| 6WIO Fab antigen complex Deposited 2020-04-10 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain C
1–155（155 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8；294 K；20% PEG 3350 + 200mM Ammonium Chloride
|
Resolution 2.17 Å R-free 0.227 |
| 6WIR Fab antigen complex Deposited 2020-04-10 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain C
1–155（155 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；274 K；100mM Hepes pH 7, 15% PEG4K, 200mM Magnesium Chloride
|
Resolution 2.96 Å R-free 0.260 |
| 7AMA IL-17A in complex with small molecule modulators Deposited 2020-10-08 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
42–150（109 aa）
Chain B
42–150（109 aa）
|
Not recorded | RMK ~{N}-[(2~{S})-1,1-dicyclopropyl-3-[[4-(3,5-dimethyl-1~{H}-pyrazol-4-yl)phenyl]amino]-3-oxidanylidene-propan-2-yl]-2-propan-2-yl-pyrazole-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 10 000, isopropanol, sodium citrate
|
Resolution 2.48 Å R-free 0.255 |
| 7AMG IL-17A in complex with small molecule modulators Deposited 2020-10-08 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
42–150（109 aa）
Chain B
42–150（109 aa）
|
Not recorded | RMQ (3~{R})-4-[4-[[(2~{S})-2-[[2,2-bis(fluoranyl)-2-phenyl-ethanoyl]amino]-3-(2-chlorophenyl)propanoyl]amino]phenyl]-3-[[(2~{S})-3-methyl-2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethanoylamino]butanoyl]amino]butanoic acid × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 10000, isopropanol, sodium citrate
|
Resolution 3.18 Å R-free 0.227 |
| 7AMG IL-17A in complex with small molecule modulators Deposited 2020-10-08 | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
42–150（109 aa）
Chain D
42–150（109 aa）
|
Not recorded | RMQ (3~{R})-4-[4-[[(2~{S})-2-[[2,2-bis(fluoranyl)-2-phenyl-ethanoyl]amino]-3-(2-chlorophenyl)propanoyl]amino]phenyl]-3-[[(2~{S})-3-methyl-2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethanoylamino]butanoyl]amino]butanoic acid × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 10000, isopropanol, sodium citrate
|
Resolution 3.18 Å R-free 0.227 |
| 7UWM Structure of the IL-17A-IL-17RA binary complex Deposited 2022-05-03 | Assembly 1 Other combination Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain A
25–155（131 aa）
Chain B
25–155（131 aa）
Chain D
25–155（131 aa）
Chain E
25–155（131 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 7 | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.50 Å |
| 7UWN Structure of the IL-17A-IL-17RA-IL-17RC ternary complex Deposited 2022-05-03 | Assembly 1 Other combination Heteromer；Protein × 7 PDB declaration: heptameric（7） Consistent with protein count |
Chain A
24–155（132 aa）
Chain B
24–155（132 aa）
Chain D
24–155（132 aa）
Chain E
24–155（132 aa）
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 9 | ELECTRON MICROSCOPY |
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.01 Å |
| 7WKX IL-17A in complex with the humanized antibody HB0017 Deposited 2022-01-12 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain E
20–155（136 aa）
Chain F
20–155（136 aa）
|
Not recorded | MLA MALONIC ACID × 7 ACY ACETIC ACID × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；4% v/v Tacsimate pH 7.0, 12% w/v Polyethylene glycol 3,350
|
Resolution 2.81 Å R-free 0.254 |
| 7Z2M Crystal Structure of the 11.003 Fab in complex with human IL-17A Deposited 2022-02-28 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain J
34–155（122 aa）
Chain K
34–155（122 aa）
|
Not recorded | GOL GLYCEROL × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2M sodium potassium tartrate, 20% (w/v) PEG 3,350
|
Resolution 1.90 Å R-free 0.227 |
| 7Z2M Crystal Structure of the 11.003 Fab in complex with human IL-17A Deposited 2022-02-28 | Assembly 2 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain G
34–155（122 aa）
Chain I
34–155（122 aa）
|
Not recorded | GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；0.2M sodium potassium tartrate, 20% (w/v) PEG 3,350
|
Resolution 1.90 Å R-free 0.227 |
| 7ZAN Crystal Structure of human IL-17A in complex with IL-17RA and IL-17RC Deposited 2022-03-22 | Assembly 1 Protein heterocomplex Heteromer；Protein × 8 PDB declaration: octameric（8） Consistent with protein count |
Chain A
34–155（122 aa）
Fragment：IL-17A
Chain B
34–155（122 aa）
Fragment：IL-17A
|
Mutation：N68D,C129S Mutation：N68D,C129S | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 8 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；293 K；0.1M MES, 10.0% PEG DME 500
|
Resolution 5.06 Å R-free 0.353 |
| 8B7W Complex IL-17A/anti-IL-17A-76 Deposited 2022-10-03 | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric（4） Consistent with protein count |
Chain C
34–155（122 aa）
|
Not recorded | GOL GLYCEROL × 2 CL CHLORIDE ION × 2 SO4 SULFATE ION × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；297 K；1.05 M NaCl, 7% v/v ethanol, 30% glycerol.
|
Resolution 2.85 Å R-free 0.265 |
| 8CDG Crystal structure of human IL-17A cytokine in complex with macrocycle Deposited 2023-01-30 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | UTF (9~{S},12~{R},19~{S})-9-[[4-[[(2~{S})-2-cyclohexyl-2-(2-phenylethanoylamino)ethanoyl]amino]phenyl]methyl]-12-methyl-7,10,13,21-tetrakis(oxidanylidene)-8,11,14,20-tetrazaspiro[4.17]docosane-19-carboxylic acid × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；291 K；100 mM sodium citrate buffer, pH 5.5, 8 % 2-propanol, and 10 % w/v PEG10k
|
Resolution 2.90 Å R-free 0.257 |
| 8DY1 Crystal Structure of scFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
35–155（121 aa）
|
Mutation：K93Q, C129S, A155Q | SO4 SULFATE ION × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；298 K；100 mM Tris, 200 mM LiSO4, 18% PEG 3350
|
Resolution 2.68 Å R-free 0.268 |
| 8DY1 Crystal Structure of scFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain B
35–155（121 aa）
|
Mutation：K93Q, C129S, A155Q | SO4 SULFATE ION × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；298 K；100 mM Tris, 200 mM LiSO4, 18% PEG 3350
|
Resolution 2.68 Å R-free 0.268 |
| 8DY5 Crystal Structure of spFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
35–155（121 aa）
|
Mutation：K93Q, C129S, A155Q | CL CHLORIDE ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；400 mM LiSO4, 15.5% PEG 3350
|
Resolution 2.20 Å R-free 0.232 |
| 8DY5 Crystal Structure of spFv CAT2200 LH in complex with IL-17A Deposited 2022-08-03 | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain D
35–155（121 aa）
|
Mutation：K93Q, C129S, A155Q | CA CALCIUM ION × 1 MG MAGNESIUM ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；400 mM LiSO4, 15.5% PEG 3350
|
Resolution 2.20 Å R-free 0.232 |
| 8DYF IL17A homodimer bound to Compound 10 Deposited 2022-08-04 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | U5I (5M)-3-[({2-[2-(2-{2-[2-({[(5M)-3-carboxy-5-(5,8-dihydroquinolin-4-yl)phenyl]amino}methyl)phenoxy]ethoxy}ethoxy)ethoxy]phenyl}methyl)amino]-5-(quinolin-4-yl)benzoic acid × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；290.15 K；3.2M NaCl, 0.1M Tris, pH 8.5
|
Resolution 2.02 Å R-free 0.259 |
| 8DYG IL17A homodimer bound to Compound 7 Deposited 2022-08-04 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | U5Q (5P)-2-hydroxy-5-(6-methylquinolin-5-yl)benzoic acid × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；290.15 K；1.6-2.0M Sodium Formate, 0.1M Tris, pH 7.8-8.8
|
Resolution 1.49 Å R-free 0.233 |
| 8DYH IL17A homodimer bound to Compound 6 Deposited 2022-08-04 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | U5X (5P)-N-benzyl-6-chloro-5-(quinolin-5-yl)pyridin-3-amine × 2 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；290.15 K；3.2M NaCl, 0.1M Tris, pH 8.5
|
Resolution 1.94 Å R-free 0.248 |
| 8DYI IL17A homodimer bound to Compound 5 Deposited 2022-08-04 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | U6C (5P)-5-[5-(benzylamino)pyridin-3-yl]-N-[2-(morpholin-4-yl)ethyl]-1H-indazol-3-amine × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；290.15 K；3.2M NaCl, 0.1M Tris, pH 8.5
|
Resolution 2.28 Å R-free 0.311 |
| 8USR IL17A homodimer complexed to Compound 23 Deposited 2023-10-29 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | XCE ~{N}-[(2~{S})-1-[[(1~{S})-1-(8~{a}~{H}-imidazo[1,2-a]pyrimidin-2-yl)ethyl]amino]-1-oxidanylidene-4-phenyl-butan-2-yl]-4,5-bis(chloranyl)-1~{H}-pyrrole-2-carboxamide × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；2 M NaCl, 0.1 M NaH2PO4, 0.1 M KH2PO4, 0.1 M MES pH 6.5
|
Resolution 1.83 Å R-free 0.250 |
| 8USR IL17A homodimer complexed to Compound 23 Deposited 2023-10-29 | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
34–155（122 aa）
Chain D
34–155（122 aa）
|
Not recorded | XCE ~{N}-[(2~{S})-1-[[(1~{S})-1-(8~{a}~{H}-imidazo[1,2-a]pyrimidin-2-yl)ethyl]amino]-1-oxidanylidene-4-phenyl-butan-2-yl]-4,5-bis(chloranyl)-1~{H}-pyrrole-2-carboxamide × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；290 K；2 M NaCl, 0.1 M NaH2PO4, 0.1 M KH2PO4, 0.1 M MES pH 6.5
|
Resolution 1.83 Å R-free 0.250 |
| 8USS IL17A complexed to Compound 7 Deposited 2023-10-29 | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric（1） Consistent with protein count |
Chain A
34–155（122 aa）
|
Not recorded | XCW 4,5-dichloro-N-[(1S)-1-cyclohexyl-2-{[(3S)-5-methyl-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepin-3-yl]amino}-2-oxoethyl]-1H-pyrrole-2-carboxamide × 1 CL CHLORIDE ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；296 K；15% w/v PEG 8K, 0.2 M MgCl2, 0.1 M Tris pH 8.5
|
Resolution 1.47 Å R-free 0.235 |
| 9FKX Crystal structure of IL-17A in complex with compound 18 Deposited 2024-06-04 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | A1IDT (4~{S})-1-[(~{R})-[2-[(~{S})-[4,4-bis(fluoranyl)cyclohexyl]-[[5-[1,1-bis(fluoranyl)ethyl]-1,3,4-oxadiazol-2-yl]amino]methyl]imidazo[1,2-b]pyridazin-7-yl]-cyclopropyl-methyl]-4-(trifluoromethyl)imidazolidin-2-one × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；0.1M citrate pH 5.5
10% PEG 10,000
12% isopropanol
10% ethylene glycol
|
Resolution 2.05 Å R-free 0.252 |
| 9FL3 Crystal structure of IL-17A in complex with compound 26 Deposited 2024-06-04 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | A1IDS (~{E})-~{N}-[(~{S})-[4,4-bis(fluoranyl)cyclohexyl]-[7-[(1~{S})-2-methoxy-1-[(4~{S})-2-oxidanylidene-4-(trifluoromethyl)imidazolidin-1-yl]ethyl]imidazo[1,2-b]pyridazin-2-yl]methyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；0.1M citrate pH 5.5
10% PEG 10,000
12% isopropanol
10% ethylene glycol
|
Resolution 2.07 Å R-free 0.252 |
| 9H4D Crystal structure of IL-17A in complex with compound 18 Deposited 2024-10-18 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | A1ISH (E)-N-[(1S)-1-[4,4-bis(fluoranyl)cyclohexyl]-2-oxidanylidene-2-[[5-[(2-oxidanylidene-3H-benzimidazol-1-yl)methyl]-1,3-thiazol-2-yl]amino]ethyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；293 K；0.1M citric acid pH 5.5
10% PEG 10000
12% iso-propanol
10% ethylene glycol
|
Resolution 2.12 Å R-free 0.241 |
| 9H4O Crystal structure of IL-17A in complex with compound 11 Deposited 2024-10-21 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | SO4 SULFATE ION × 5 A1ISG (E)-N-[(1S)-1-[4,4-bis(fluoranyl)cyclohexyl]-2-oxidanylidene-2-[[5-[[(4S)-2-oxidanylidene-4-(trifluoromethyl)imidazolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]ethyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.5；293 K；0.1 M bis-tris pH 5.5
0.2 M lithium sulfate monohydrate
25% PEG 3350
|
Resolution 2.00 Å R-free 0.262 |
| 9H4O Crystal structure of IL-17A in complex with compound 11 Deposited 2024-10-21 | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
34–155（122 aa）
Chain D
34–155（122 aa）
|
Not recorded | SO4 SULFATE ION × 2 A1ISG (E)-N-[(1S)-1-[4,4-bis(fluoranyl)cyclohexyl]-2-oxidanylidene-2-[[5-[[(4S)-2-oxidanylidene-4-(trifluoromethyl)imidazolidin-1-yl]methyl]-1,3-thiazol-2-yl]amino]ethyl]-3-cyclopropyl-2-fluoranyl-prop-2-enamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.5；293 K；0.1 M bis-tris pH 5.5
0.2 M lithium sulfate monohydrate
25% PEG 3350
|
Resolution 2.00 Å R-free 0.262 |
| 9SFX Secukinumab Fv in complex with human IL-17A Deposited 2025-08-21 | Assembly 1 Protein heterocomplex Heteromer；Protein × 10 PDB declaration: decameric（10） Consistent with protein count |
Chain C
20–155（136 aa）
|
Not recorded | GOL GLYCEROL × 8 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 4.6；292 K；0.1M sodium acetate pH 4.6, 1.8M ammonium citrate dibasic
|
Resolution 2.60 Å R-free 0.213 |
| 9SG0 CJM112 Fv in complex with human IL-17A Deposited 2025-08-21 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain A
24–155（132 aa）
|
Not recorded | SO4 SULFATE ION × 2 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；292 K；0.1M MES pH 6.5, 0.2M ammonium sulfate, 15% PEG 5,000 MME
|
Resolution 2.65 Å R-free 0.256 |
| 9SG2 Ixekizumab Fab in complex with human IL-17A Deposited 2025-08-21 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain A
20–155（136 aa）
|
Not recorded | No recorded non-water small molecule | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；0.1M TRIS pH 8.5, 40% MPD
|
Resolution 2.92 Å R-free 0.246 |
| 9SGH Bimekizumab Fab in complex with human interleukin-17A Deposited 2025-08-22 | Assembly 1 Protein heterocomplex Heteromer；Protein × 6 PDB declaration: hexameric（6） Consistent with protein count |
Chain I
34–155（122 aa）
Chain J
34–155（122 aa）
|
Mutation：C129S Mutation：C129S | ZN ZINC ION × 6 PO4 PHOSPHATE ION × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.5；292 K；0.2M zinc acetate, 0.1M imidazole pH 6.5, 10% PEG 8,000
|
Resolution 2.66 Å R-free 0.253 |
| 9SQI Crystal structure of IL-17A in complex with compound 21 Deposited 2025-09-22 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | A1JPQ ~{N}-[(~{S})-[3-[[(6~{R})-3-bromanyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl]methyl]-1~{H}-1,2,4-triazol-5-yl]-cyclohexyl-methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 7 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M lithium sulfate
0.1M Bis-Tris pH 5.5
25% PEG 3,350
|
Resolution 1.48 Å R-free 0.226 |
| 9SQI Crystal structure of IL-17A in complex with compound 21 Deposited 2025-09-22 | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
34–155（122 aa）
Chain D
34–155（122 aa）
|
Not recorded | A1JPQ ~{N}-[(~{S})-[3-[[(6~{R})-3-bromanyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-6-yl]methyl]-1~{H}-1,2,4-triazol-5-yl]-cyclohexyl-methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 4 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.2M lithium sulfate
0.1M Bis-Tris pH 5.5
25% PEG 3,350
|
Resolution 1.48 Å R-free 0.226 |
| 9SQX Crystal structure of IL-17A in complex with compound 19 Deposited 2025-09-23 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | A1JPS ~{N}-[(~{S})-cyclohexyl-[3-[(4-oxidanylidene-3~{H}-phthalazin-1-yl)methyl]-1~{H}-1,2,4-triazol-5-yl]methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 5 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.2M lithium sulfate
0.1M Bis-Tris pH 5.5
25% PEG 3,350
|
Resolution 1.41 Å R-free 0.227 |
| 9SQX Crystal structure of IL-17A in complex with compound 19 Deposited 2025-09-23 | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
34–155（122 aa）
Chain D
34–155（122 aa）
|
Not recorded | A1JPS ~{N}-[(~{S})-cyclohexyl-[3-[(4-oxidanylidene-3~{H}-phthalazin-1-yl)methyl]-1~{H}-1,2,4-triazol-5-yl]methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 SO4 SULFATE ION × 5 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；0.2M lithium sulfate
0.1M Bis-Tris pH 5.5
25% PEG 3,350
|
Resolution 1.41 Å R-free 0.227 |
| 9SR8 Crystal structure of IL-17A in complex with compound 22 Deposited 2025-09-24 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
34–155（122 aa）
Chain B
34–155（122 aa）
|
Not recorded | A1JPU ~{N}-[(~{S})-[3-[[7-bromanyl-3-methyl-2,4-bis(oxidanylidene)quinazolin-1-yl]methyl]-1~{H}-1,2,4-triazol-5-yl]-cyclohexyl-methyl]-4-methyl-1,2,5-oxadiazole-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；0.1M citrate pH 5.5
10% PEG 10,000
12% isopropanol
10% ethylene glycol
|
Resolution 2.56 Å R-free 0.254 |
| 9YIC Crystal structure of human IL-17A in complex with Compound 1 Deposited 2025-10-01 | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain A
35–155（121 aa）
Chain B
35–155（121 aa）
|
Not recorded | A1CXF (3S)-N-[(3-{[(1S)-2-anilino-1-cyclohexyl-2-oxoethyl]carbamoyl}phenyl)methyl]-2,2-dimethylthiomorpholine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；295.15 K；13.7% PEG 6000, 0.1M sodium malonate pH 4.0, 1.3% methyl-2,4-pentanediol
|
Resolution 3.15 Å R-free 0.242 |
| 9YIC Crystal structure of human IL-17A in complex with Compound 1 Deposited 2025-10-01 | Assembly 2 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric（2） Consistent with protein count |
Chain C
35–155（121 aa）
Chain D
35–155（121 aa）
|
Not recorded | A1CXF (3S)-N-[(3-{[(1S)-2-anilino-1-cyclohexyl-2-oxoethyl]carbamoyl}phenyl)methyl]-2,2-dimethylthiomorpholine-3-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray crystallization conditions
VAPOR DIFFUSION；295.15 K；13.7% PEG 6000, 0.1M sodium malonate pH 4.0, 1.3% methyl-2,4-pentanediol
|
Resolution 3.15 Å R-free 0.242 |